钠-葡萄糖协同转运蛋白2抑制剂对IgA肾病肾脏保护作用的研究进展

doi:10.3969/j.issn.1004-583X.2022.11.017

摘要/Abstract

摘要：

IgA肾病(IgA nephropathy,IgAN)是我国最常见的原发性肾小球疾病,也是引起终末期肾病(end-stage renal disease,ESRD)的重要原因,可发生于任何年龄段,但以青年男性最为多见。钠-葡萄糖协同转运蛋白2(sodium-glucose transporter 2,SGLT2)抑制剂是一种新型降糖药物,已在2型糖尿病(diabetes mellitus type 2,T2DM)患者中广泛应用。随着认识的不断深入,研究发现SGLT2抑制剂不仅可降低IgAN患者尿蛋白与血压、调节肾脏血流动力学、控制尿酸及体重,甚至对肾脏炎症及纤维化也有着积极的影响,可通过多种途径对肾脏起保护作用,有望治疗和延缓IgAN。本文通过对SGLT2抑制剂对IgAN肾脏保护的研究进展进行综述,旨在提供理论依据。

中图分类号:

R692.31

张鹏伟, 程霞, 程兰兰, 赵慧, 马志刚. 钠-葡萄糖协同转运蛋白2抑制剂对IgA肾病肾脏保护作用的研究进展[J]. 临床荟萃, 2022, 37(11): 1053-1056.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2022.11.017

https://huicui.hebmu.edu.cn/CN/Y2022/V37/I11/1053

参考文献 40

[1]	Berger J, Hinglais N. Les ddpôts intercapillaires d'IgA-IgG [Intercapillary deposits of IgA-IgG]. J Urol Nephrol (Paris), 1968, 74(9):694-695. pmid: 4180586
[2]	Rajasekaran A, Julian BA, Rizk DV. IgA nephropathy: An interesting autoimmune kidney disease[J]. Am J Med Sci, 2021, 361(2):176-194. doi: 10.1016/j.amjms.2020.10.003 pmid: 33309134
[3]	Lai KN, Tang SC, Schena FP, et al. IgA nephropathy[J]. Nat Rev Dis Primers, 2016, 2:16001. doi: 10.1038/nrdp.2016.1 pmid: 27189177
[4]	Liu ZH. Nephrology in China[J]. Nat Rev Nephrol, 2013, 9(9):523-528. doi: 10.1038/nrneph.2013.146 URL
[5]	Maixnerova D, Tesar V. Emerging modes of treatment of IgA nephropathy[J]. Int J Mol Sci, 2020, 21(23):9064. doi: 10.3390/ijms21239064 URL
[6]	Heerspink H, Perco P, Mulder S, et al. Canagliflozin reduces inflammation and fibrosis biomarkers: A potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease[J]. Diabetologia, 2019, 62(7):1154-1166. doi: 10.1007/s00125-019-4859-4 pmid: 31001673
[7]	Packer M. Role of impaired nutrient and oxygen deprivation signaling and deficient autophagic flux in diabetic CKD development:Implications for understanding the effects of sodium-glucose cotransporter 2-inhibitors[J]. J Am Soc Nephrol, 2020, 31(5):907-919. doi: 10.1681/ASN.2020010010 URL
[8]	Kobayashi K, Toyoda M, Hatori N, et al. Retrospective analysis of the renoprotective effects of long-term use of six types of sodium-glucose cotransporter 2 inhibitors in Japanese patients with type 2 diabetes mellitus and chronic kidney disease[J]. Diabetes Technol Ther, 2021, 23(2):110-119. doi: 10.1089/dia.2020.0165 URL
[9]	Wan N, Rahman A, Hitomi H, et al. The effects of sodium-glucose cotransporter 2 inhibitors on sympathetic nervous activity[J]. Front Endocrinol (Lausanne), 2018, 9:421. doi: 10.3389/fendo.2018.00421 URL
[10]	Hussain M, Elahi A, Hussain A, et al. Sodium-glucose cotransporter-2 (SGLT-2) attenuates serum uric acid (SUA) level in patients with type 2 diabetes[J]. J Diabetes Res, 2021, 2021:9973862.
[11]	Barbour S, Reich H. An update on predicting renal progression in IgA nephropathy[J]. Curr Opin Nephrol Hypertens, 2018, 27(3):214-220. doi: 10.1097/MNH.0000000000000405 URL
[12]	陈天新, 陈波, 陈薪薪, 等. 伴与不伴原发性肾病的恶性高血压肾损害临床病理特点及预后对比分析[J]. 中华肾脏病杂志, 2019, 35(12):906-913. doi: 10.3760/cma.j.issn.1001-7097.2019.12.005
[13]	Kario K, Ferdinand KC, O'Keefe JH. Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease[J]. Prog Cardiovasc Dis, 2020, 63(3):249-262. doi: S0033-0620(20)30074-8 pmid: 32275926
[14]	Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes[J]. N Engl J Med, 2017, 377(7):644-657. doi: 10.1056/NEJMoa1611925 URL
[15]	Sarraju A, Spencer-Bonilla G, Rodriguez F, et al. Canagliflozin and cardiovascular outcomes in type 2 diabetes[J]. Future Cardiol, 2021, 17(1):39-48. doi: 10.2217/fca-2020-0029 URL
[16]	Mosenzon O, Wiviott SD, Heerspink H, et al. The effect of dapagliflozin on albuminuria in DECLARE-TIMI 58[J]. Diabetes Care, 2021, 44(8):1805-1815. doi: 10.2337/dc21-0076 pmid: 34233928
[17]	McMurray J, Docherty KF, Jhund PS. Dapagliflozin in patients with heart failure and reduced ejection fraction.reply[J]. N Engl J Med, 2020, 382(10):973.
[18]	Latva-Rasku A, Honka MJ, Kullberg J, et al. The SGLT 2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: A randomized, double-blind, placebo-controlled study with 8-week treatment in type 2 diabetes patients[J]. Diabetes Care, 2019, 42(5):931-937. doi: 10.2337/dc18-1569 pmid: 30885955
[19]	Nishad R, Mukhi D, Tahaseen SV, et al. Growth hormone induces Notch1 signaling in podocytes and contributes to proteinuria in diabetic nephropathy[J]. J Biol Chem, 2019, 294(44):16109-16122. doi: 10.1074/jbc.RA119.008966 pmid: 31511328
[20]	Inker LA, Heerspink H, Tighiouart H, et al. Association of treatment effects on early change in urine protein and treatment effects on GFR slope in IgA nephropathy:An individual participant meta-analysis[J]. Am J Kidney Dis, 2021, 78(3):340-349. doi: 10.1053/j.ajkd.2021.03.007 URL
[21]	Kidney Disease: Improving Global Outcomes KDIGO Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases[J]. Kidney Int, 2021, 100(4S):S1-S276. doi: 10.1016/j.kint.2021.05.021 pmid: 34556256
[22]	Cherney D, Zinman B, Inzucchi SE, et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: An exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial[J]. Lancet Diabetes Endocrinol, 2017, 5(8):610-621. doi: 10.1016/S2213-8587(17)30182-1 URL
[23]	Barratt J, Floege J. SGLT-2 inhibition in IgA nephropathy: The new standard of care?[J]. Kidney Int, 2021, 100(1):24-26. doi: 10.1016/j.kint.2021.04.002 URL
[24]	丁丽娜, 吴丽华, 周晓玲, 等. IgA肾病患者血清氧化应激相关指标水平与肾间质纤维化的相关性[J]. 中华肾脏病杂志, 2019, 35(5):336-341. doi: 10.3760/cma.j.issn.1001-7097.2019.05.003
[25]	毕志军. IgA肾病患者与转化生长因子β1相关性研究[J]. 中国药物与临床, 2019, 19(1):36-38.
[26]	Kanwar YS, Sun L, Xie P, et al. A glimpse of various pathogenetic mechanisms of diabetic nephropathy[J]. Annu Rev Pathol, 2011, 6:395-423. doi: 10.1146/annurev.pathol.4.110807.092150 pmid: 21261520
[27]	Ojima A, Matsui T, Nishino Y, et al. Empagliflozin, an inhibitor of sodium-glucose cotransporter 2 exerts anti-inflammatory and antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-receptor Axis[J]. Horm Metab Res, 2015, 47(9):686-692. doi: 10.1055/s-0034-1395609 pmid: 25611208
[28]	Dekkers C, Petrykiv S, Laverman GD, et al. Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers[J]. Diabetes Obes Metab, 2018, 20(8):1988-1993. doi: 10.1111/dom.13301 pmid: 29573529
[29]	Ishibashi Y, Matsui T, Yamagishi S. Tofogliflozin, a highly selective inhibitor of SGLT2 blocks proinflammatory and proapoptotic effects of glucose overload on proximal tubular cells partly by suppressing oxidative stress generation[J]. Horm Metab Res, 2016, 48(3):191-195. doi: 10.1055/s-0035-1555791 pmid: 26158396
[30]	Ni L, Yuan C, Chen G, et al. SGLT2i: Beyond the glucose-lowering effect[J]. Cardiovasc Diabetol, 2020, 19(1):98. doi: 10.1186/s12933-020-01071-y pmid: 32590982
[31]	邱强, 陈香美, 谢院生, 等. 影响IgA肾病高尿酸血症的因素[J]. 中国中西医结合肾病杂志, 2005, 6(6):329-331.
[32]	李玉凤, 董云萍, 蒋红樱, 等. IgA肾病患者高尿酸血症的影响因素分析[J]. 临床肾脏病杂志, 2021, 21(5):411-415.
[33]	Wu C, Wang AY, Li G, et al. Association of high body mass index with development of interstitial fibrosis in patients with IgA nephropathy[J]. BMC Nephrol, 2018, 19(1):381. doi: 10.1186/s12882-018-1164-2 pmid: 30594167
[34]	Fishman B, Shlomai G, Twig G, et al. Renal glucosuria is associated with lower body weight and lower rates of elevated systolic blood pressure: Results of a nationwide cross-sectional study of 2.5 million adolescents[J]. Cardiovasc Diabetol, 2019, 18(1):124. doi: 10.1186/s12933-019-0929-7 pmid: 31554505
[35]	刘会芳, 王晓辉, 鲁娟, 等. 高尿酸血症对IgA肾病临床及病理特点影响的探讨[J]. 中国中西医结合肾病杂志, 2020, 21(1):47-49.
[36]	Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: The CONFIRMS trial[J]. Arthritis Res Ther, 2010, 12(2):R63. doi: 10.1186/ar2978 URL
[37]	McGill JB. The SGLT2 inhibitor empagliflozin for the treatment of type 2 diabetes mellitus: A bench to bedside review[J]. Diabetes Ther, 2014, 5(1):43-63. doi: 10.1007/s13300-014-0063-1 pmid: 24729157
[38]	Wheeler DC, Toto RD, Stefánsson BV, et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy[J]. Kidney Int, 2021, 100(1):215-224. doi: 10.1016/j.kint.2021.03.033 pmid: 33878338
[39]	侯凡凡. SGLT2抑制剂对慢性肾脏病患者的作用[J]. 中华医学信息导报, 2021, 36(5):19.
[40]	Authors N. UK Kidney Association Clinical Practice Guideline:Sodium-glucose co-transporter-2 (SGLT-2) inhibition in adults with kidney disease[J]. Pochki, 2022, 11(1):30-36.

钠-葡萄糖协同转运蛋白2抑制剂对IgA肾病肾脏保护作用的研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 40

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王涛, 高玉伟, 王兴华, 胡秀红, 崔红蕊, 徐保振, 杨洪娟. 抗磷脂酶A2受体抗体与特发性膜性肾病的相关性[J]. 临床荟萃, 2023, 38(7): 606-612.
[2]	高秦宇, 包蓓艳, 金燕, 赵宇. IgA肾病合并抑郁状态患者的临床特征和预后影响因素分析[J]. 临床荟萃, 2023, 38(6): 510-515.
[3]	高鹏丽, 陈丽丽, 田芬, 张嘉倩, 陈怿鹏, 亓晓菁, 邢广群. 体质量指数对IgA肾病患者临床病理及预后的影响[J]. 临床荟萃, 2022, 37(3): 234-242.
[4]	刘一坤, 刘冰, 冯珍. 抗磷脂酶A2受体抗体在原发性膜性肾病患者中的研究进展[J]. 临床荟萃, 2021, 36(6): 569-573.
[5]	刘佳丽, 谢荣, 李雪莲, 刘晓惠. 中性粒细胞/淋巴细胞比值与IgA肾病Lee氏分级、牛津分型的相关性分析[J]. 临床荟萃, 2021, 36(5): 432-435.
[6]	李雷婷;李冰. 特发性膜性肾病治疗进展[J]. 临床荟萃, 2013, 28(3): 342-347.
[7]	白会玲;陈丽辉. 通络祛湿法治疗70例IgA肾病临床观察[J]. 临床荟萃, 2012, 27(17): 1540-1542.
[8]	葛晓;王艳丽;杨莉娅;陈俊峰;刘必成. 环孢素A治疗特发性膜性肾病的荟萃分析[J]. 临床荟萃, 2012, 27(3): 196-201.
[9]	马之学;尹智炜;王丹云;吕乐远. 干细胞移植治疗IgA肾病1例[J]. 临床荟萃, 2010, 25(23): 2100-0.
[10]	杨林;张丽萍;李绍梅. 膜性肾病合并抗基底膜性肾小球肾炎及Castleman病1例[J]. 临床荟萃, 2010, 25(18): 1645-1646.
[11]	吴亚;魏宏莲;郄会卿. 血清脂肪细胞型脂肪酸结合蛋白测定在慢性原发性肾小球肾炎的临床意义[J]. 临床荟萃, 2009, 24(24): 2161-2162.
[12]	杨林;张丽萍;王建荣;杨万霞. 尿常规正常IgA肾病1例[J]. 临床荟萃, 2009, 24(21): 1932-1932.
[13]	杨林;段惠军. IgA肾病的预后及其影响因素[J]. 临床荟萃, 2007, 22(21): 1594-0.
[14]	傅淑霞;邢玲玲;裴华颖;李绍梅;杨林;王彦. 糖皮质激素所致胰岛素抵抗的影响因素及临床[J]. 临床荟萃, 2007, 22(16): 1144-1147.
[15]	张靖;张兰芝;温慧;张红梅. 银屑病合并IgA肾病8例临床与病理分析[J]. 临床荟萃, 2006, 21(14): 1034-1035.